Rho Executive and Leadership Team

Lawrence Morentz, the Chief Executive Officer at Rho, directs the overarching strategic vision and long-term growth trajectory of the organization. By aligning clinical research capabilities with evolving pharmaceutical industry demands, Morentz ensures the company maintains a competitive edge in drug development services. The Chief Executive Officer oversees high-level interactions with the Board to secure sustainable expansion across North American and international markets. Through rigorous focus on operational excellence, Morentz drives the integration of diverse research functions to support complex client portfolios. This leadership role involves fostering a culture of scientific integrity and innovation that defines the company market position. Lawrence Morentz consistently evaluates emerging therapeutic trends to refine the corporate roadmap. By prioritizing client success and regulatory compliance, the Chief Executive Officer strengthens the reputation of the firm as a premier partner in the global clinical research landscape.

Michael Szarowicz, the Chief Financial Officer at Rho, governs the financial health and fiscal strategy of the organization. By managing capital allocation, budgeting, and long-term financial planning, the Chief Financial Officer ensures the company possesses the resources necessary to sustain complex clinical research operations. Szarowicz directs financial reporting and risk management initiatives to protect the interests of the firm and its stakeholders. This leadership role involves analyzing market data to inform investment decisions in new research technologies and service capabilities. Michael Szarowicz collaborates with the executive team to align fiscal performance with strategic growth targets. By maintaining rigorous financial controls, the Chief Financial Officer supports the stability of the company during periods of rapid expansion. Szarowicz also oversees the financial aspects of client contracts, ensuring profitability and operational sustainability across all drug development projects within the global market.

Stas Johnson-Chyzhykov, the Chief Operating Officer at Rho, manages the daily execution of clinical research projects and internal resource allocation. Overseeing the efficiency of cross-functional teams, the Chief Operating Officer optimizes workflows to ensure timely delivery of drug development milestones. Johnson-Chyzhykov coordinates with department heads to streamline project management processes, thereby enhancing productivity across all research phases. This leadership role requires constant monitoring of operational metrics to maintain high standards of quality and compliance. By implementing scalable systems, Stas Johnson-Chyzhykov supports the expansion of service capacity to meet increasing demand from global biotechnology clients. The Chief Operating Officer also facilitates communication between technical staff and executive leadership to ensure project alignment with corporate objectives. Through meticulous oversight of operational infrastructure, Johnson-Chyzhykov secures the stability and reliability of the entire clinical research service delivery model.

Deborah Johnson, the President at Rho, leads the execution of corporate initiatives and manages the overall business performance of the organization. By overseeing the alignment of departmental goals with the broader mission of the company, the President ensures consistent progress in clinical research service delivery. Johnson coordinates with the executive team to refine business development strategies and expand the market presence of the firm. This leadership role involves fostering strong relationships with key industry partners and clients to drive long-term growth. Deborah Johnson monitors the competitive landscape to identify opportunities for service diversification and operational improvement. By championing organizational culture and professional development, the President empowers teams to achieve excellence in every clinical project. Through strategic leadership and a focus on client-centric solutions, Johnson strengthens the position of the company as a trusted leader in the global drug development industry.

Biljana Djordjevic, the Technology Chief of Staff at Rho, architects the digital infrastructure and data management systems essential for modern clinical research. Overseeing the implementation of advanced software solutions, the Technology Chief of Staff ensures that all research data remains secure, accurate, and accessible. Djordjevic coordinates with IT teams to integrate new technologies that enhance the efficiency of drug development processes. This leadership role involves bridging the gap between technical requirements and business goals to drive digital transformation across the organization. Biljana Djordjevic manages the deployment of analytical tools that provide actionable insights for clinical trial management. By fostering a culture of technological innovation, the Technology Chief of Staff enables the company to maintain a leading position in the competitive CRO industry. Through strategic oversight of digital assets, Djordjevic ensures that the firm remains at the forefront of data-driven clinical research excellence.

Andrew Feigin, the Chief Medical Officer at Rho, provides clinical expertise and scientific leadership across the entire drug development lifecycle. Overseeing the medical integrity of clinical trials, the Chief Medical Officer ensures that all research protocols adhere to the highest safety and regulatory standards. Feigin directs the medical monitoring teams to evaluate patient safety and data quality throughout complex study phases. This leadership role involves advising clients on therapeutic strategy and regulatory pathways to optimize the success of drug development programs. Andrew Feigin collaborates with internal research teams to interpret clinical findings and guide the progression of pharmaceutical assets. By maintaining deep knowledge of therapeutic areas, the Chief Medical Officer supports the firm in delivering high-quality scientific outcomes. Through rigorous medical oversight, Feigin ensures that the company consistently meets the evolving needs of the global healthcare and biotechnology sectors.